Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase I, Multi-center Study to Determine the Recommended Dose of CYAD-211 After a Non-myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients With Relapsed or Refractory Disease

NCT04613557 is registered in ClinicalTrials.gov with Celyad Oncology SA as lead sponsor.

NCT NCT04613557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04613557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase I, Multi-center Study to Determine the Recommended Dose of CYAD-211 After a Non-myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients With Relapsed or Refractory Disease
Lead sponsor
Celyad Oncology SA
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 16, 2020
Completion date
February 28, 2037
Enrollment
18 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

relapse/refractory multiple myeloma